Herein, we describe the expression of survivin/BIRC5 and XIAP in ET, PV, and PMF patients and JAK2V617F cell lines and the molecular and cellular effects of treatment with YM155 in MPN cellular models. This evidence concerns the gene BIRC5 and myeloproliferative neoplasm.